YouTube took down a video Friday posted by the bio-tech firm Aytu BioSience explaining a new UV light treatment for coronavirus patients. Aytu BioScience announced Tuesday the firm is working with Cedars-Sinai and the FDA to determine the efficacy of the treatment.
The video is now labeled, “This video has been removed for violating YouTube’s Terms of Service”.
Original video with now dead link:
Copy posted and live for now:
Aytu BioScience promoted the video on Twitter Friday morning, “Many are now talking about UV light being used as a treatment for COVID-19. We are proud to have teamed up with @MarkPimentelMD and his team at @CedarsSinai. They developed Healight. Peer-reviewed data will be published in days, but here’s how it works:”
Many are now talking about UV light being used as a treatment for COVID-19. We are proud to have teamed up with @MarkPimentelMD and his team at @CedarsSinai. They developed Healight. Peer-reviewed data will be published in days, but here’s how it works: https://t.co/9E6dyOkwhI
— Aytu_BioScience (@BioscienceAytu) April 24, 2020
Aytu BioScience said this evening on Twitter that YouTube has not told them why the video was taken down, “That’s correct. We do not have any idea why. Our team has asked for clarification.”
That’s correct. We do not have any idea why. Our team has asked for clarification.
— Aytu_BioScience (@BioscienceAytu) April 25, 2020
With no explanation from YouTube forthcoming, Aytu BioScience posted the video to Vimeo Friday night:
There is incredible interest in our UV light technology developed by @MarkPimentelMD and his team at @CedarsSinai For reasons still unclear, YouTube disabled the link. If you’re interested in how our technology is designed to work, here is a new link. https://t.co/n1dkFGRlLH
— Aytu_BioScience (@BioscienceAytu) April 25, 2020
An excerpt from the video can also be seen at RushLimbaugh.com
Excerpt from the Aytu BioScience press release this week:
ENGLEWOOD, CO / ACCESSWIRE / April 20, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the “Company”), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has signed an exclusive worldwide license from Cedars-Sinai to develop and commercialize the Healight Platform Technology (“Healight”). This medical device technology platform, discovered and developed by scientists at Cedars-Sinai, is being studied as a potential first-in-class treatment for coronavirus and other respiratory infections.
The company will host a live conference call and webcast Tuesday, April 21, 2020 at 4:30 p.m. ET. Conference call details are provided at the end of this press release.
Led by Mark Pimentel, MD, the research team of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai has been developing the patent-pending Healight platform since 2016 and has produced a growing body of scientific evidence demonstrating pre-clinical safety and effectiveness of the technology as an antiviral and antibacterial treatment. The Healight technology employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel endotracheal medical device. Pre-clinical findings indicate the technology’s significant impact on eradicating a wide range of viruses and bacteria, inclusive of coronavirus. The data have been the basis of discussions with the FDA for a near-term path to enable human use for the potential treatment of coronavirus in intubated patients in the intensive care unit (ICU). Beyond the initial pursuit of a coronavirus ICU indication, additional data suggest broader clinical applications for the technology across a range of viral and bacterial pathogens. This includes bacteria implicated in ventilator associated pneumonia (VAP).
“Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells,” stated Dr. Pimentel of Cedars-Sinai. Ali Rezaie, MD, one of the inventors of this technology states, “Our lab at Cedars-Sinai has extensively studied the effects of this unique technology on bacteria and viruses. Based on our findings we believe this therapeutic approach has the potential to significantly impact the high morbidity and mortality of coronavirus-infected patients and patients infected with other respiratory pathogens. We are looking forward to partnering with Aytu BioScience to move this technology forward for the benefit of patients all over the world.”
The company believes the Healight platform technology has the potential to positively impact outcomes for critically ill patients infected with coronavirus and severe respiratory infections. The company licensed exclusive worldwide rights to the technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. Patents have been filed by Cedars-Sinai Department of Technology Transfer, and Aytu BioScience will manage all aspects of intellectual property prosecution and filing globally. Aytu BioScience expects to partner the product outside the U.S.
“We are honored to be partnering with Cedars-Sinai as we believe the Healight therapeutic platform has the potential to help many patients during this coronavirus pandemic and beyond,” said Josh Disbrow, Chairman and CEO of Aytu BioScience.
The Company is engaging with the research team at Cedars-Sinai and the FDA to determine an expedited regulatory process to potentially enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.
Disbrow continued, “This first-in-class technology has the potential to be a game changer for clinicians treating patients infected with coronavirus and other respiratory conditions, and our team is working tirelessly alongside the Cedars-Sinai team to determine the safety and effectiveness of this device in humans.”